Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer

Seri Jeong, Yongjung Park, Yonggeun Cho, Young Ran Kim, Hyon Suk Kim

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background We compared the diagnostic utilities of CYFRA 21‐1, nuclear matrix protein-22 (NMP22), urinary bladder cancer antigen (UBC), and fibrin/fibrinogen degradation products (FDP) for detecting urinary bladder cancer. Methods We assayed CYFRA 21‐1, NMP22, UBC and FDP from urine samples for 250 subjects. Among them, 54 were diagnosed as bladder cancer, and the remaining 196, which consisted of healthy individuals and patients with hematuria, inflammation/infection, or benign prostate hyperplasia, were assigned to the control group. Results Urinary levels of all 4 markers were higher in the bladder cancer group than the control group. The areas under the receiver operating characteristic curves (ROC-AUCs) of CYFRA 21‐1, NMP22, UBC and FDP, corrected with urine creatinine concentrations, were 0.90, 0.89, 0.80 and 0.77, respectively, for discriminating bladder cancer from controls. The ROC-AUCs for the combinations of the markers were not significantly higher than those with CYFRA 21‐1 or NMP22. NMP22 was the only independent variable for predicting bladder cancer among the four markers in the multivariate analysis. Conclusions All 4 tumor biomarkers exhibited diagnostic utility for predicting bladder cancer. Among them, CYFRA 21‐1 and NMP22 were the most effective at predicting bladder cancer.

Original languageEnglish
Pages (from-to)93-100
Number of pages8
JournalClinica Chimica Acta
Volume414
DOIs
Publication statusPublished - 2012 Dec 24

Fingerprint

Urinary Bladder Neoplasms
Fibrinogen
Urine
Antigens
Degradation
Fibrin Fibrinogen Degradation Products
ROC Curve
Area Under Curve
Tumor Biomarkers
nuclear matrix protein 22
Creatinine
Control Groups
Hematuria
Hyperplasia
Prostate
Multivariate Analysis
Inflammation
Infection

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Jeong, Seri ; Park, Yongjung ; Cho, Yonggeun ; Kim, Young Ran ; Kim, Hyon Suk. / Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer. In: Clinica Chimica Acta. 2012 ; Vol. 414. pp. 93-100.
@article{1a526bcd1e6743d08b795e0b291480c4,
title = "Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer",
abstract = "Background We compared the diagnostic utilities of CYFRA 21‐1, nuclear matrix protein-22 (NMP22), urinary bladder cancer antigen (UBC), and fibrin/fibrinogen degradation products (FDP) for detecting urinary bladder cancer. Methods We assayed CYFRA 21‐1, NMP22, UBC and FDP from urine samples for 250 subjects. Among them, 54 were diagnosed as bladder cancer, and the remaining 196, which consisted of healthy individuals and patients with hematuria, inflammation/infection, or benign prostate hyperplasia, were assigned to the control group. Results Urinary levels of all 4 markers were higher in the bladder cancer group than the control group. The areas under the receiver operating characteristic curves (ROC-AUCs) of CYFRA 21‐1, NMP22, UBC and FDP, corrected with urine creatinine concentrations, were 0.90, 0.89, 0.80 and 0.77, respectively, for discriminating bladder cancer from controls. The ROC-AUCs for the combinations of the markers were not significantly higher than those with CYFRA 21‐1 or NMP22. NMP22 was the only independent variable for predicting bladder cancer among the four markers in the multivariate analysis. Conclusions All 4 tumor biomarkers exhibited diagnostic utility for predicting bladder cancer. Among them, CYFRA 21‐1 and NMP22 were the most effective at predicting bladder cancer.",
author = "Seri Jeong and Yongjung Park and Yonggeun Cho and Kim, {Young Ran} and Kim, {Hyon Suk}",
year = "2012",
month = "12",
day = "24",
doi = "10.1016/j.cca.2012.08.018",
language = "English",
volume = "414",
pages = "93--100",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer. / Jeong, Seri; Park, Yongjung; Cho, Yonggeun; Kim, Young Ran; Kim, Hyon Suk.

In: Clinica Chimica Acta, Vol. 414, 24.12.2012, p. 93-100.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer

AU - Jeong, Seri

AU - Park, Yongjung

AU - Cho, Yonggeun

AU - Kim, Young Ran

AU - Kim, Hyon Suk

PY - 2012/12/24

Y1 - 2012/12/24

N2 - Background We compared the diagnostic utilities of CYFRA 21‐1, nuclear matrix protein-22 (NMP22), urinary bladder cancer antigen (UBC), and fibrin/fibrinogen degradation products (FDP) for detecting urinary bladder cancer. Methods We assayed CYFRA 21‐1, NMP22, UBC and FDP from urine samples for 250 subjects. Among them, 54 were diagnosed as bladder cancer, and the remaining 196, which consisted of healthy individuals and patients with hematuria, inflammation/infection, or benign prostate hyperplasia, were assigned to the control group. Results Urinary levels of all 4 markers were higher in the bladder cancer group than the control group. The areas under the receiver operating characteristic curves (ROC-AUCs) of CYFRA 21‐1, NMP22, UBC and FDP, corrected with urine creatinine concentrations, were 0.90, 0.89, 0.80 and 0.77, respectively, for discriminating bladder cancer from controls. The ROC-AUCs for the combinations of the markers were not significantly higher than those with CYFRA 21‐1 or NMP22. NMP22 was the only independent variable for predicting bladder cancer among the four markers in the multivariate analysis. Conclusions All 4 tumor biomarkers exhibited diagnostic utility for predicting bladder cancer. Among them, CYFRA 21‐1 and NMP22 were the most effective at predicting bladder cancer.

AB - Background We compared the diagnostic utilities of CYFRA 21‐1, nuclear matrix protein-22 (NMP22), urinary bladder cancer antigen (UBC), and fibrin/fibrinogen degradation products (FDP) for detecting urinary bladder cancer. Methods We assayed CYFRA 21‐1, NMP22, UBC and FDP from urine samples for 250 subjects. Among them, 54 were diagnosed as bladder cancer, and the remaining 196, which consisted of healthy individuals and patients with hematuria, inflammation/infection, or benign prostate hyperplasia, were assigned to the control group. Results Urinary levels of all 4 markers were higher in the bladder cancer group than the control group. The areas under the receiver operating characteristic curves (ROC-AUCs) of CYFRA 21‐1, NMP22, UBC and FDP, corrected with urine creatinine concentrations, were 0.90, 0.89, 0.80 and 0.77, respectively, for discriminating bladder cancer from controls. The ROC-AUCs for the combinations of the markers were not significantly higher than those with CYFRA 21‐1 or NMP22. NMP22 was the only independent variable for predicting bladder cancer among the four markers in the multivariate analysis. Conclusions All 4 tumor biomarkers exhibited diagnostic utility for predicting bladder cancer. Among them, CYFRA 21‐1 and NMP22 were the most effective at predicting bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=84866290702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866290702&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2012.08.018

DO - 10.1016/j.cca.2012.08.018

M3 - Article

C2 - 22944145

AN - SCOPUS:84866290702

VL - 414

SP - 93

EP - 100

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -